MPP signs on four generics makers to make Novartis' Tasigna more accessible
The Medicines Patent Pool has set up sublicense agreements with four manufacturers to produce generic versions of Novartis’ cancer drug Tasigna, as part of an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
